The Pharmacy and Therapeutic Committee met on March 15th to review several new drug applications and formulary additions. They discussed the benefits and risks of the diabetes drug Metaglip and agreed to add it to the formulary with restrictions. The committee also reviewed the requests to add the antibiotics Cefdinir and Cefprozil to the formulary and voted to accept both additions.
The Pharmacy and Therapeutic Committee met on March 15th to review several new drug applications and formulary additions. They discussed the benefits and risks of the diabetes drug Metaglip and agreed to add it to the formulary with restrictions. The committee also reviewed the requests to add the antibiotics Cefdinir and Cefprozil to the formulary and voted to accept both additions.
The Pharmacy and Therapeutic Committee met on March 15th to review several new drug applications and formulary additions. They discussed the benefits and risks of the diabetes drug Metaglip and agreed to add it to the formulary with restrictions. The committee also reviewed the requests to add the antibiotics Cefdinir and Cefprozil to the formulary and voted to accept both additions.
The Pharmacy and Therapeutic Committee met on March 15th to review several new drug applications and formulary additions. They discussed the benefits and risks of the diabetes drug Metaglip and agreed to add it to the formulary with restrictions. The committee also reviewed the requests to add the antibiotics Cefdinir and Cefprozil to the formulary and voted to accept both additions.